LBF20107PG08: Difference between revisions
No edit summary |
No edit summary |
||
(15 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
Line 4: | Line 6: | ||
|LipidBank=XPR1731 | |LipidBank=XPR1731 | ||
|LipidMaps=LMFA03010049 | |LipidMaps=LMFA03010049 | ||
|SysName= 9alpha,15S- | |SysName=(9alpha,15S) -Dihydroxy-11-oxo-prost-trans-13-en-1-oic acid | ||
|Common Name=&&Prostaglandin D_1&&9alpha,15S- | |Common Name=&&Prostaglandin D_1&&(9alpha,15S) -Dihydroxy-11-oxo-prost-13(E)-en-1-oic acid&& | ||
|Source= | |||
|Chemical Synthesis= | |||
|Metabolism= | |||
|Biological Activity=Prostaglandin D1 inhibits ADP-induced human platelet aggregation effect (IC50 value of 320 ng/ml). [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790|{{RelationTable/GetFirstAuthor|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]Prostaglandin D1 inhibits the increase in vascular permeability in rat skin produced by prostaglandin E1, E2 and D2.[[Reference:Flower_RJ:Kingston_WP:,Br. J. Pharmacol.,1975,55,239P|{{RelationTable/GetFirstAuthor|Reference:Flower_RJ:Kingston_WP:,Br. J. Pharmacol.,1975,55,239P}}]] PGD1 is equal in activity to PGF1 alpha in causing constriction of central and peripheral airways of the dog.[[Reference:Spannhake_EW:Levin_JL:Hyman_AL:Kadowitz_PJ:,Prostaglandins Leukot. Essent. Fatty Acids,1983,10,123|{{RelationTable/GetFirstAuthor|Reference:Spannhake_EW:Levin_JL:Hyman_AL:Kadowitz_PJ:,Prostaglandins Leukot. Essent. Fatty Acids,1983,10,123}}]] | |||
}} | }} | ||
{{Lipid/Footer}} |
Latest revision as of 17:04, 21 October 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR1731 |
LipidMaps | LMFA03010049 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20107PG08 |
Prostaglandin D1 | |
---|---|
![]() | |
Structural Information | |
(9α,15S) -Dihydroxy-11-oxo-prost-trans-13-en-1-oic acid | |
| |
Formula | C20H32O4 |
Exact Mass | 336.23005951199997 |
Average Mass | 336.46567999999996 |
SMILES | C(CC[C@H](O)C=C[C@H]([C@H]1CCCCCCC(O)=O)C=CC(=O)1)CC |
Physicochemical Information | |
Prostaglandin D1 inhibits ADP-induced human platelet aggregation effect (IC50 value of 320 ng/ml). Bundy_GL et al.Prostaglandin D1 inhibits the increase in vascular permeability in rat skin produced by prostaglandin E1, E2 and D2. Flower_RJ et al. PGD1 is equal in activity to PGF1 alpha in causing constriction of central and peripheral airways of the dog. Spannhake_EW et al. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
[hide]Reported Metabolites, References | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|